Jim Cramer Maintains Position in Eli Lilly (LLY) Amid Strong Obesity Drug Pipeline
Eli Lilly's stock continues to rise, driven by promising data on its obesity drug retatrutide, prompting analysts and investors to maintain their positions despite the stock's significant gains.